Distribution of subtypes and immunophenotypic characterization of 1379 cases of paediatric acute leukaemia

Abstract

Objectives: Acute leukaemia is the most common and highly curable childhood malignancy; subtyping and identification of antigens via immunophenotyping helps in treatment plan as well as minimal residual disease monitoring.
 Methods: This retrospective study was conducted at the Haematology section of the clinical laboratories of Ziauddin University Hospital and The Indus Hospital, Karachi conducted at January 1st, 2012 to December 31st, 2017. The study included 1379 cases of de novo acute leukemia from 2012 to 2017. Among these, 80% were diagnosed by using four color flowcytometry (FACS Calibur), 9% and 11% via immunohistochemistry on bone marrow trephine biopsy samples and morphological examination respectively.
 Results: The mean age of patients was 7.4 ± 4.3 years while male to female ratio was 1.75:1. Lymphoblastic leukaemia accounted for 77.2% and myeloid leukaemia 21.2%. Amongst lymphoblastic lineage, B-ALL was 80.4% while T-ALL was 19.6%. Among the phenotypic expression of B-ALL, CD79a (99.8%) had the highest positivity. In B-ALL, CD13 (29.8%) was the most common aberrant myeloid marker. Aberrant expression of CD79a observed in 11.1% of T-ALL cases. In non APL AML, aberrant expression of CD79a and CD19 was observed in 6.6% and 5.5% of cases respectively.
 Conclusion: Overall immunophenotypic profile, expression of aberrant phenotypes and subtype distribution in our patients was similar to international literature except for a relatively high frequency of T-ALL which was discordant from the western data.
 doi: https://doi.org/10.12669/pjms.37.3.3552
 How to cite this:Jamal S, Meraj F, Mansoor N, Parveen S, Shaikh A, Jabbar N. Distribution of subtypes and immunophenotypic characterization of 1379 cases of paediatric acute leukaemia. Pak J Med Sci. 2021;37(3):---------. doi: https://doi.org/10.12669/pjms.37.3.3552
 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PAX5 and TDT-Negative B-Acute Lymphoblastic Leukemia with Unusual Genetic Mutations: A Case Report

“…In two studies, the frequency of TDT-negative among a series of B-ALL ranged between 2.5 and 11%, where it was evaluated by both FC and immunohistochemistry (IHC). 2 4 5 Another larger study of 917 patients demonstrated a TDT-negative rate of 2.3%, which was examined by FC only. 6 The authors found that TDT-negative patients tended to be younger, had high WBC count, and carried KMT2A-r mutation.…”

Chromosome-1 abnormalities in Childhood B-Lymphoblastic Leukemia – An analysis with reference to clinical variables and survival outcome

“…The most common childhood cancer is acute lymphoblastic leukemia (ALL), with 80-85% of cases coming from the B lineage. 1 , 2 Childhood B lymphoblastic leukemia (B-ALL) usually has a good prognosis, with a cure rate approaching 90% in high-income countries. 3 , 4 This improvement in outcome is a result of appropriate risk stratification, the introduction of risk-adjusted treatment protocols, and better supportive care.…”

Aberrant Expression of CD19 in Early T-cell Precursor Lymphoblastic Leukemia- A Diagnostic Challenge

“…CD3 is a pan-T cell marker expressed by T-lymphocytes throughout the maturation spectrum. CD19 is a lineage specific marker for B-cells and its expression in T-cell neoplasms is rarely found [3]. CD79a, another marker of B-lineage is reported to be aberrantly expressed in Tlymphoblastic leukemia (T-ALL) while CD19 expression is exceptionally rare in T-ALL.…”